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Pre-participation cardiac 
screening: Considerations  
for young athletes
The sudden death of a young, apparently healthy athlete is a shocking, highly publicized event that results in a unified outpouring of emotion from both 
the media and general public alike. The incidence of 
sudden cardiac death (SCD) was thought to be reassuringly 
low with figures between 1: 160 000 cases and 1: 300 000 
cases per year in athletes between the ages of 14 and 35 
years in the United States (Van Camp et al, 1995; Maron et 
al, 2009). However, other recent data has shown a ten-fold 
increase in incidence. For example, in the Veneto region of 
Italy, a regional registry recording deaths of young athletes 
from SCD (ages 12–35 years) reported incidence rates of 
1:28 000 prior to the implementation of a screening 
programme (Corrado et al, 2006). Similar incidence 
figures (1:27 000) in children and young adults aged 14–24 
years were also reported in 11 US and Canadian cities 
(Atkins et al, 2009). 
Therefore, the real incidence of SCD in young athletes is 
difficult to determine as many published studies use very 
different methodologies, and sample populations are often 
from different geographical locations making inter-study 
comparisons difficult (Drezner et al, 2009). Consequently, 
early studies may have greatly underestimated the true 
risk of SCD in young athletic populations. It would appear 
that males have a ten-fold greater incidence of SCD than 
females (Burke et al, 1999; Corrado et al, 2005; Corrado et 
al, 2006), perhaps as they are more likely to be engaged in 
competitive sports and greater training volumes than 
females. The demographic profile of a typical young per-
son likely to be affected by SCD would be a young active 
male aged 15–22 years (Corrado et al, 2006). 
To prevent SCD, a cardiac condition must initially be 
identified followed by an appropriate treatment pathway 
based on individual circumstances, which could involve 
surgery, device implantation, lifestyle alterations, pharma-
cological intervention, or a combination of these therapies 
(Anderson and Vetter, 2009). The first stage of the process 
is to identify the cardiac condition and for young athletes 
this may be through a pre-participation cardiac screening 
programme. 
Pre-participation cardiac screening is an investigative 
tool designed to provide medical clearance for participa-
tion in sports through a systematic interrogation of indi-
vidual cardiovascular health (Wilson et al. 2008). Specific 
modes of pre-participation screening have been debated 
within the scientific community for many years. Such 
debates are informed by issues of cost-effectiveness, rates 
of false positives and negatives, and ethical and legal con-
cerns. 
Several professional governing bodies including the 
European Society of Cardiology (ESC), International 
Olympic Committee (IOC), and the Fédération 
Internationale de Football Association (FIFA) have pro-
duced consensus statements recommending standard 
cardiac screening programmes that include, at the initial 
stage, a combination of resting electrocardiography 
(ECG), personal symptoms, and physical examination. 
The American Heart Association (AHA) pre-participa-
tion screening programme focuses specifically on per-
sonal symptoms and physical examination (Maron et al, 
2007). It anticipates that an extra annual programme cost 
of $2 billion would be required to include a resting ECG 
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This article is the first of two focusing on the utility and evidence base 
for pre-participation cardiac screening in competitive athletic 
populations. The second article will focus on the diagnostic value of 
different screening modalities used in the large-scale screening of 
athletic populations. The current article, however, focuses on the 
incidence of sudden cardiac death (SCD) in  young athletic populations 
and goes on to consider the effectiveness of cardiac screening 
programmes for reducing the risk of SCD. 
Cardiac screening in athletic populations is problematic as it may 
be difficult to distinguish between physiological adaptations resulting 
from a specific exercise training stimulus and pathological conditions. 
Different types of chronic exercise training can induce eccentric or 
concentric myocardial hypertrophy, which may mimic pathological 
conditions. The final section discusses some of the practical issues 
that a clinician may face when needing to advise a young athlete to 
either stop or modify his/her habitual patterns of physical activity 
including future exercise considerations.
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examination. However, the US system is under close scru-
tiny as 80% of athletes who die as a result of SCD are 
asymptomatic and physical examination identifies few 
relevant disorders (Papadakis et al, 2008). 
Effectiveness of cardiac screening 
programmes
In Italy, mandatory screening of all athletes through the 
Medical Protection of Athletic Activities Act has been in 
existence since 1979, and in excess of 6  million athletes 
have been screened (Corrado et al, 2005). The Italian 
model has seen a reduction in incidence of SCD from 3.6 
cases per 100 000 per year before screening to 0.4 cases per 
100 000 per year reported in 2003–2004 (Corrado et al, 
2006). These data represent a 90% reduction in mortality 
since pre-participation screening was introduced and offer 
compelling evidence for the inclusion of a cardiac screen-
ing programme. 
The physiological versus pathological heart
Long-term exercise training results in adaptations to car-
diac structure and function. These alterations may appear 
to be confusing to the uninitiated as they may mimic spe-
cific pathological abnormalities that could result in heart 
disease (Huston et al, 1985). The type of exercise training 
conducted is the key stimulus for the type of cardiac adap-
tation achieved. For example, endurance or aerobic train-
ing such as distance running, cycling or swimming will, 
over time, result in increased maximal oxygen uptake and 
cardiac output, leading to increased volume load on the 
left ventricle. Conversely, long-term strength training 
activities such as weight lifting and wrestling may result in 
little change in maximal oxygen uptake and cardiac output 
but will result in pressure overload on the left ventricle 
(Maron, 2009). 
In approximately 50% of athletes, long-term exercise 
training results in some degree of cardiac remodelling 
which may be evident on the ECG trace in ways that 
resemble pathological chamber enlargement and/or may 
mimic patterns seen in, for example, hypertrophic cardio-
myopathy (Mitchell et al, 2005).
Pathological and physiological myocardial hypertro-
phy can be sub-classified into concentric or eccentric 
hypertrophy based on morphological changes that are 
dependent on the initial stimulus (Pluim et al, 2000). A 
pathological stimulus causing pressure overload (e.g. 
hypertension or aortic stenosis) produces an increase in 
systolic wall stress resulting in concentric hypertrophy) 
(McMullen and Jennings, 2007) (Figure 1). Conversely, a 
pathological stimulus causing volume overload (e.g. aor-
tic regurgitation) results in an increase in diastolic wall 
stress and consequently leads to eccentric hypertrophy 
(Pluim et al, 2000). 
In healthy athletic populations, long-term endurance/
aerobic training may lead to increases in cardiac chamber 
size and left-ventricular mass (eccentric hypertrophy). 
Resting heart rate may be reduced (bradycardia) leading 
to excessive vagal tone at rest. This can produce abnor-
malities such as atrioventricular block and wandering 
atrial pacemaker on the resting ECG (Crawford, 2007). 
Furthermore, low resting heart rate (<60  bpm) may 
increase the frequency of premature ventricular contrac-
tions and short runs of ventricular tachycardia may be 
evident. However, in the trained athlete these rhythm dis-
turbances often disappear following the start of exercise 
(Biffi et al, 2002). 
Sophisticated cardiac imaging techniques such as 
echocardiographic deformation imaging have recently 
revealed that a moderate reduction in regional septal 
deformation should not be considered as pathological in 
endurance athletes with left ventricular hypertrophy 
(Teske et al, 2009). Long-term strength training, such as in 
weight-lifters, may increase left-ventricular wall thickness 
(up to 16  mm) and left-ventricular mass (concentric 
hypertrophy) (Pelliccia et al, 1991; Crawford, 2007). 
Highly trained athletes with cardiac chamber enlargement 
may also have systolic flow murmurs, and third and fourth 
heart sounds (Crawford, 2007). 
For more detailed information on sport-specific chang-
es in left-ventricular cavity size and wall thickness the 
interested reader is directed to Maron (2009). 
Risks of exercise in athletes with cardiac 
conditions
The holistic benefits of exercise and physical activity are 
firmly established in the public health domain. However, 
while the incidence of cardiac-related deaths is very low, 
Endurance or aerobic training will lead to changes in the  
heart over time, as may strength training
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there may be associated risks of exercise in individuals 
with underlying cardiac conditions. Vigorous exercise is 
more likely to trigger ventricular arrhythmias and SCD in 
vulnerable individuals (Maron, 2003). 
Following screening, if a cardiac abnormality is identi-
fied, the young athlete’s clinician should provide a recom-
mendation for sports participation and provide general 
advice relating to habitual physical activity. Guidelines 
such as those published by the ESC should be used to 
assist clinical judgments (Pelliccia et al, 2005). For exam-
ple, sudden bursts of acceleration involving high intensity 
activity should be avoided as should extreme environ-
ments (hot, cold, altitude, hyperbaric), and more ‘danger-
ous’ sports such as parachuting and bungee jumping. 
Performance enhancing and/or recreational drugs includ-
ing stimulants should also be avoided. Low to moderate 
forms of exercise intensity such as recreational jogging or 
cycling, which involve a suitable warm-up and cool-down, 
may be more appropriate. 
The clinician must weigh the theoretical increased risk 
of SCD associated with the engagement in exercise against 
the psychosocial and health benefits of sports participa-
tion (Anderson and Vetter, 2009). However, there is no 
guarantee that the young athlete will follow the medical 
guidance. Often a compromise between clinician and 
young athlete will be sought allowing, for example, the 
athlete to continue some level of engagement in a less 
demanding position (such as moving from an outfield 
player to a goalkeeper in football) (Anderson and Vetter, 
2009). Such compromises need to be carefully evaluated 
by the clinician and will require consent from the coach of 
the specific sports team. 
Clearly, there are a number of ethico-legal considera-
tions balancing clinical necessity and psycho-social and 
health benefits from the perspective of the young athlete, 
which should be carefully considered before any final 
decision is reached. 
Screening in the UK
In the UK, the charity Cardiac Risk in the Young (CRY) 
has been involved in cardiac screening for around 15 
years, initially on an ad hoc basis. In recent years, since 
large-scale investment from the technology company 
Phillips, CRY has developed a nationally co-ordinated 
screening programme known as ‘Save an Athlete’. However, 
the future role for cardiac screening in the UK is still 
under debate. Professional sporting associations need to 
evaluate the need for the development of clear and com-
prehensive screening programmes while carefully balanc-
ing the financial implications that such initiatives would 
no doubt involve.
Conclusions
Concern over the possibility that strenuous exercise may 
trigger previously undetected cardiac conditions in young 
athletes, causing sudden death, has led to the introduction 
of pre-participation screening programmes. In looking for 
abnormalities, health professionals need to take into 
account changes to the heart’s structure and function that 
are the result of long-term excercise training. 
While screening programmes are mandatory in some 
countries, in the UK their role is still under consideration. 
A further article will consider various models used for 
screening athletes for risk of SCD.
Anderson BR, Vetter VL (2009) Return to play? Practical considerations 
for young athletes with cardiovascular disease. Br J Sports Med 43: 
690–5
Atkins DL, Everson-Stewart S, Sears GK et al (2009) Epidemiology and 
outcomes from out-of-hospital cardiac arrest in children: the 
Resuscitation Outcomes Consortium Epistry-Cardiac Arrest. 
Circulation 119: 1484–91
Biffi A, Pelliccia A, Verdile L et al (2002) Long-term clinical significance 
of frequent and complex ventricular tachyarrhythmias in trained ath-
letes. J Am Coll Cardiol 40: 446–52
Burke AP, Robinson S, Radentz S, Smialek J, Virmani R (1999) Sudden 
death in right ventricular dysplasia with minimal gross abnormali-
ties. J Forensic Sci 44: 438–43
Corrado D, Pelliccia A, Bjørnstad HH et al (2005) Cardiovascular pre-
participation screening of young competitive athletes for prevention 
of sudden death: proposal for a common European protocol - 
Consensus statement of the Study Group of Sport Cardiology of the 
Working Group of Cardiac Rehabilitation and Exercise Physiology 
and the Working Group of Myocardial and Pericardial Diseases of 
the European Society of Cardiology. Eur Heart J 26: 516–24
Corrado D, Basso C, Pavei A, Michieli P, Schiavon M, Thiene G (2006) 
Trends in sudden cardiovascular death in young competitive athletes 
after implementation of a preparticipation screening program. JAMA 
296: 1593–601
Crawford MH (2007) Screening athletes for heart disease. Heart 93(7): 
875–9
Drezner J, Pluim B, Engebretsen L (2009) Prevention of sudden cardiac 
death in athletes: new data and modern perspectives confront chal-
lenges in the 21st century. Br J Sports Med 43: 625–6
Huston TP, Puffer JC, Rodney WM (1985) The athletic heart syndrome. 
N Engl J Med 313: 24–32
Maron BJ (2003). Sudden death in young athletes. N Engl J Med 
349(11): 1064–75
Maron BJ (2009) Distinguishing hypertrophic cardiomyopathy from 
athlete’s heart physiological remodelling: clinical significance, diag-
nostic strategies and implications for preparticipation screening.  
Br J Sports Med 43: 649–56
Maron BJ, Thompson PD, Ackerman MJ et al (2007) Recommendations 
Symmetric or 
concentric 
hypertrophy
Figure 1. Concentric hypertrophy may be seen in 
conditions where there is pressure overload, but may also 
be seen in those undertaking long-term strength training.
4 British Journal of Cardiac Nursing    August 2010    Vol 5 No 8
Clinical
and considerations related to pre-participation screening for cardiovas-
cular abnormalities in competitive athletes: 2007 update: a scientific 
statement from the American Heart Association Council on Nutrition, 
Physical Activity, and Metabolism: endorsed by the American College 
of Cardiology Foundation. Circulation 115: 1643–55
Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO (2009) Sudden 
deaths in young competitive athletes: analysis of 1866 deaths in the 
United States, 1980-2006. Circulation 119: 1085–92
McMullen JR, Jennings GL (2007) Differences between pathological 
and physiological cardiac hypertrophy: novel therapeutic strategies 
to treat heart failure. Clin Exp Pharmacol Physiol 34(4): 255–62
Mitchell JH, Haskell W, Snell P, Van Camp SP (2005) Task Force 8: clas-
sification of sports. J Am Coll Cardiol 45: 1364-7
Papadakis M, Whyte G, Sharma S (2008). Preparticipation screening for 
cardiovascular abnormalities in young competitive athletes. BMJ 337: 
806–11
Pelliccia A, Maron BJ, Spataro A, Proschan MA, Spirito P (1991). The 
upper limit of physiologic cardiac hypertrophy in highly trained elite 
athletes. N Engl J Med 324: 295–301
Pelliccia A, Fagard R, Bjørnstad HH et al (2005) Recommendations for 
competitive sports participation in athletes with cardiovascular dis-
ease: a consensus document from the Study Group of Sports 
Cardiology of the Working Group of Cardiac Rehabilitation and 
Exercise Physiology and the Working Group of Myocardial and 
Pericardial Diseases of the European Society of Cardiology. Eur 
Heart J 26: 1422–45
Pluim BM, Zwinderman AH, van der Laarse A, van der Wall EE (2000) 
The athlete’s heart - A meta-analysis of cardiac structure and func-
tion. Circulation 101: 336–44
Teske AJ, Prakken NH, De Boeck BW, Velthuis BK, Doevendans PA, 
Cramer MJ (2010) Echocardiographic deformation imaging reveals 
preserved regional systolic function in endurance athletes with left 
ventricular hypertrophy. Br J Sports Med May 10 (Epub ahead of print)
Van Camp SP, Bloor CM, Mueller FO, Cantu RC, Olson HG (1995) 
Nontraumatic sports death in high school and college athletes. Med 
Sci Sports Exerc 27: 641-7
Wilson MG, Basavarajaiah S, Whyte GP, Cox S, Loosemore M, 
Sharma S (2008). Efficacy of personal symptom and family history 
questionnaires when screening for inherited cardiac pathologies: the 
role of electrocardiography. Br J Sports Med 42: 207–11
Key Points
 w The incidence of sudden cardiac death in young athletes is unclear 
as ten-fold differences have been reported in the literature
 w Pre-participation cardiac screening is an investigative tool designed 
to provide medical clearance for participation in sports through a 
systematic interrogation of individual cardiovascular health
 w In Italy, a 90% reduction in incidence of SCD has been reported 
following the introduction of a cardiac screening programme 
providing compelling evidence for its inclusion in a health screening 
package
 w Cardiac screening in athletic populations is problematic as it may be 
difficult to distinguish between physiological and pathological 
adaptations
 w In a young athlete with a cardiac abnormality, the clinician must 
carefully balance clinical necessity with the potential psycho-social 
and health benefits of continued exercise.
